Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

556
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
556
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

511
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.

Diabetes, obesity & metabolism·2015
Same author

T and Tk antigen activation in necrotising enterocolitis: manifestations, severity of illness, and effectiveness of testing.

Archives of disease in childhood. Fetal and neonatal edition·1999
Same author

Persistence of Japanese encephalitis virus in the human nervous system.

Journal of medical virology·1993
Same author

Mitral valve prolapse with Wolff-Parkinson-White syndrome.

Indian pediatrics·1991
Same author

Brucellosis in children.

Indian pediatrics·1987
Same author

Congenital syphilis with chylous ascites.

Indian pediatrics·1983

Related Experiment Video

Updated: Mar 2, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.

M H Barghash1, A S Desai1

  • 1Advanced Heart Disease Section, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|May 18, 2017
PubMed
Summary

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is recommended for heart failure with reduced ejection fraction (HFrEF). This review covers its efficacy, rationale, and practical guidance for use.

More Related Videos

Nitropeptide Profiling and Identification Illustrated by Angiotensin II
07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

6.2K
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

17.1K

Related Experiment Videos

Last Updated: Mar 2, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

6.2K
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

17.1K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Sacubitril/valsartan is a novel angiotensin receptor-neprilysin inhibitor (ARNI).
  • It targets both the renin-angiotensin system and neprilysin activity.
  • Enhanced levels of vasoactive peptides contribute to its therapeutic effects.

Purpose of the Study:

  • To review the scientific rationale for neprilysin inhibition in cardiovascular disease.
  • To summarize the clinical trial data supporting the efficacy of sacubitril/valsartan.
  • To provide practical recommendations for the clinical use of sacubitril/valsartan.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of data from landmark trials, including PARADIGM-HF.
  • Synthesis of expert opinion and clinical guidelines.

Main Results:

  • Neprilysin inhibition increases beneficial natriuretic peptides and reduces detrimental angiotensin II effects.
  • The PARADIGM-HF trial demonstrated superior efficacy of sacubitril/valsartan over enalapril in HFrEF.
  • Sacubitril/valsartan significantly reduces cardiovascular mortality and morbidity in HFrEF patients.

Conclusions:

  • Sacubitril/valsartan represents a significant advancement in HFrEF management.
  • Understanding the mechanism and evidence base is crucial for optimal patient selection.
  • Practical implementation strategies are essential for maximizing patient benefit.